Charles River - JP Morgan Conference Presentation
Balanced revenue contribution and robust growth profile
19%
RMS
Research Models
Research Model Services
Human Cellular Products
(Cell Supply)
9.5%
organic growth
LTM 3Q22
26.3%
non-GAAP
operating margin
LTM 3Q22
Total
Revenue
60%
DSA
21%
Manufacturing*
-
-
Discovery Services
Safety Assessment
12.6%
organic growth
LTM 3Q22
24.5%
non-GAAP
operating margin
LTM 3Q22
Microbial Solutions
Biologics Testing
C> CDMO
8.6%
organic growth
LTM 3Q22
31.6%
non-GAAP
operating income
LTM 3Q22
Charles River - JP Morgan Conference Presentation
See ir.criver.com for reconciliations of GAAP to non-GAAP results.
All revenue and operating income/margin figures based on LTM September 2022 financial information.
Note: Charles River completed the previously announced divestiture of the Avian Vaccine business in December 2022. Avian is included in the LTM 2022 figures above.
8View entire presentation